Evan/ Fa Jones Net Worth

The estimated Net Worth of Evan/ Fa Jones is at least 13.3 百万$ dollars as of 12 August 2024. Evan Jones owns over 47,845 units of Veracyte Inc stock worth over 156,845$ and over the last 14 years Evan sold VCYT stock worth over 13,181,628$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Evan Jones VCYT stock SEC Form 4 insiders trading

Evan has made over 53 trades of the Veracyte Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Evan sold 47,845 units of VCYT stock worth 1,540,131$ on 12 August 2024.

The largest trade Evan's ever made was buying 874,317 units of Veracyte Inc stock on 19 May 2016 worth over 26,509,291$. On average, Evan trades about 25,182 units every 60 days since 2011. As of 12 August 2024 Evan still owns at least 5,173 units of Veracyte Inc stock.

You can see the complete history of Evan Jones stock trades at the bottom of the page.

What's Evan Jones's mailing address?

Evan's mailing address filed with the SEC is 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Veracyte Inc

Over the last 11 years, insiders at Veracyte Inc have traded over 201,983,044$ worth of Veracyte Inc stock and bought 75,122 units worth 1,149,322$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Nicole Vitullo、Jesse I Treu. On average, Veracyte Inc executives and independent directors trade stock every 20 days with the average trade being worth of 804,905$. The most recent stock trade was executed by John Leite on 4 September 2024, trading 5,479 units of VCYT stock currently worth 163,165$.

What does Veracyte Inc do?

veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .

Complete history of Evan Jones stock trades at Standard BioTools Inc、Opgen Inc、Veracyte Inc

Veracyte Inc executives and stock owners

Veracyte Inc executives and other stock owners filed with the SEC include:

• Bonnie H. Anderson,
  Co-Founder & Exec. Chairwoman
• Dr. Giulia C. Kennedy Ph.D.,
  Global Chief Scientific Officer & Chief Medical Officer
• John Walter Hanna Jr.,
  Chief Commercial Officer and GM of Endocrinology, Breast Cancer & Lymphoma
• Rebecca Chambers,
  Exec. VP & CFO
• Dr. Tina S. Nova Ph.D.,
  Pres of CLIA U.S. Bus.
• Annie McGuire,
  Sr. VP & Gen. Counsel
• Jonathan Wygant,
  VP & Chief Accounting Officer
• Robert Brainin,
  Exec. VP & Chief Bus. Officer
• Dr. Alfred Bowie Jr., Ph.D.,
  VP of Corp. & Bus. Devel.
• Tracy Morris,
  VP of Corp. Communications & Investor Relations
• William W. Zondler,
  Sr. VP & Chief Information Officer
• Beverly Jane Alley CPA,
  VP, Corp. Controller & Principal Accounting Officer
• Marc A. Stapley,
  CEO & Director
• Marc Stapley,
  Chief Executive Officer
• Rebecca Chambers,
  Chief Financial Officer
• Karin Eastham,
  Director
• Brian G Atwood,
  Director
• Keith Kennedy,
  COO / CFO
• Christopher M Hall,
  Chief Commercial Officer
• Perkins Caufield & Byers Xi...,
  
• John L Bishop,
  Director
• Evan/ Fa Jones,
  Director
• Fred E Cohen,
  Director
• Shelly D Guyer,
  Chief Financial Officer
• Robert S Epstein,
  Director
• Kevin K Gordon,
  Director
• Muna Bhanji,
  Director
• Julie Brooks,
  EVP,General Counsel,Secretary
• Jesse I Treu,
  Director
• Giulia C Kennedy,
  Chief Scientific & Med Officer
• Bonnie H Anderson,
  Director
• Ventures Iii, Llc Versant V...,
  
• Viii Associates, L.P. Dp,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Brook H Byers,
  Director
• Brian K Halak,
  10% owner
• Duncan Thomas Powell,
  Principal Accounting Officer
• Partners Viii, L.P.Blair Ja...,
  
• Samuel D Colella,
  Director
• Brian H Dovey,
  10% owner
• Nicole Vitullo,
  10% owner
• Partners Viii, L.P. Domain,
  10% owner
• James C Blair,
  10% owner
• John Walter Jr Hanna,
  Chief Commercial Officer
• Mark Ho,
  
• Iii James H Erlinger,
  
• Jens Holstein,
  Director
• John Leite,
  Chief Commercial Officer-CLIA
• Beverly Jane Alley,
  VP, Corporate Controller
• David Brent Shafer,
  Director
• Thomas F. Miller,
  Director
• Tina Susan Nova,
  President, CLIA U.S.
• Annie Mc Guire,
  SVP, General Counsel
• Eliav Barr,
  Director
• Jonathan Wygant,
  VP, Chief Accounting Officer
• Phillip G. Febbo,
  Chief Scientific & Med Officer